Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Salarius Pharmaceuticals ( (SLRX) ) has provided an announcement.
On November 18, 2025, Salarius Pharmaceuticals entered into employment agreements with Frederick E. Pierce, Dr. Barbara Hibner, and Peter Marschel to serve as Chief Executive Officer, Chief Scientific Officer, and Chief Business Officer, respectively. These agreements outline compensation, benefits, and conditions for termination, including severance pay and benefits under certain circumstances, reflecting strategic leadership appointments aimed at strengthening the company’s executive team.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Average Trading Volume: 1,734,976
Technical Sentiment Signal: Sell
Current Market Cap: $5.39M
For a thorough assessment of SLRX stock, go to TipRanks’ Stock Analysis page.